Physician profile
Bruce L Winter
NPI 1710976907
$2,895.20
in general payments reported to CMS, 2019-2025
22 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $272 · 2021: $457 · 2022: $287 · 2023: $261 · 2024: $588 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $451.90 | 2022-2025 | Centurion, Clareon, Hydrus Microstent |
| Biotissue Holdings INC. | $293.26 | 2025 | |
| Eyevance Pharmaceuticals LLC | $265.64 | 2021 | |
| Sun Pharmaceutical Industries INC. | $221.07 | 2019-2020 | |
| Ocular Therapeutix, INC. | $199.17 | 2021-2022 | |
| Amgen INC. | $154.19 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $143.95 | 2019-2020 | |
| Astellas Pharma US INC | $127.12 | 2024 | Izervay |
| New World Medical,INC. | $125.34 | 2024 | Kahook Dual Blade, Streamline, Ahmed Glaucoma Valve |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | Syfovre |
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.95 | 2019 | |
| Rxsight INC | $101.10 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Allergan, INC. | $99.12 | 2021 | |
| Bausch & Lomb Americas INC. | $98.51 | 2023-2025 | Xiidra, Miebo, Alrex |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.65 | 2022 | |
| Omeros Corporation | $59.92 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $38.80 | 2022 | |
| Abbvie INC. | $26.33 | 2024 | |
| Oyster Point Pharma, INC. | $21.20 | 2022 | |
| Thea Pharma INC. | $14.44 | 2023 | Iyuzeh |
| Shire North American Group INC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.